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Pancreatic duct ligation reduces 
premalignant pancreatic lesions 
in a Kras model of pancreatic 
adenocarcinoma in mice
Marta Cáceres1, Rita Quesada1, Mar Iglesias1, Francisco X. Real2, Maria Villamonte1, 
Jaime Martinez de Villarreal2, Mónica Pérez2, Ana Andaluz3, Xavier Moll3, Enrique Berjano4, 
Dimitri Dorcaratto5, Patricia Sánchez Velazquez1, Luís Grande1 & Fernando Burdío1*
Pancreatic duct ligation (PDL) in the murine model has been described as an exocrine pancreatic 
atrophy-inducing procedure. However, its influence has scarcely been described on premalignant 
lesions. This study describes the histological changes of premalignant lesions and the gene expression 
in a well-defined model of pancreatic ductal adenocarcinoma by PDL. Selective ligation of the 
splenic lobe of the pancreas was performed in Ptf1a-Cre(+/ki); K-ras  LSLG12Vgeo(+/ki) mice (PDL-Kras 
mice). Three experimental groups were evaluated: PDL group, controls and shams. The presence 
and number of premalignant lesions (PanIN 1–3 and Atypical Flat Lesions—AFL) in proximal (PP) 
and distal (DP) pancreas were studied for each group over time. Microarray analysis was performed 
to find differentially expressed genes (DEG) between PP and PD. Clinical human specimens after 
pancreaticoduodenectomy with ductal occlusion were also evaluated. PDL-Kras mice showed an 
intense pattern of atrophy in DP which was shrunk to a minimal portion of tissue. Mice in control 
and sham groups had a 7 and 10-time increase respectively of risk of high-grade PanIN 2 and 3 and 
AFL in their DP than PDL-Kras mice. Furthermore, PDL-Kras mice had significantly less PanIN 1 and 
2 and AFL lesions in DP compared to PP. We identified 38 DEGs comparing PP and PD. Among them, 
several mapped to protein secretion and digestion while others such as Nupr1 have been previously 
associated with PanIN and PDAC. PDL in Ptf1a-Cre(+/ki); K-ras  LSLG12Vgeo(+/ki) mice induces a decrease 
in the presence of premalignant lesions in the ligated DP. This could be a potential line of research of 
interest in some cancerous risk patients.
In spite of advanced basic and applied research, the prognosis of pancreatic ductal adenocarcinoma (PDAC) 
has not improved for the last 20 years, being the overall 5-year survival of less than 5%1. Only less than 20% 
patients are diagnosed early enough to benefit from a definitive surgical  treatment2,3 and PDAC is projected to 
surpass breast, prostate, and colorectal cancers as the leading cause of cancer-related death in the US by the year 
 20302. For those reasons, the development of the first genetically defined model of PDAC that recapitulates the 
morphological spectrum of the human disease was welcomed with enthusiasm. In that regard, the conditional 
knock-in  KrasG12D/+ mouse model, first described by Hingorani et al.4 has been used in basic research to study the 
importance of Kras mutations in PDAC initiation. Upon activation of mutant Kras during pancreatic develop-
ment, mice develop premalignant lesions starting at week 10 and this model has become the most widely used 
to study the evolution to  PDAC5. Additionally, atypical flat lesions (AFL) have been described in this genetically 
engineered mouse model (GEMM) of adenocarcinoma and in humans as preneoplastic  lesions6–8.
Kras mutations are one of the earliest genetic abnormalities in the progression model to  PDAC5,9. Ninety 
percent of human PDAC contain activating mutations in the GTPase signaling protein—Kras oncogene, leading 
to PanIN-sequence  initiation10,11. The p53 tumor suppressor gene is the central integrator of the cellular response 
to DNA damage and  apoptosis12,13. Loss of p53 function causes deregulation in cell death and cell  division14,15. 
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Interestingly, p53 mutation, assessed by nuclear overexpression of p53 protein, is a late event in the progression 
model of pancreatic  adenocarcinoma5,15 (Figure S1).
On the other hand, ultrastructural and immunohistochemical studies in normal and transgenic mice have 
demonstrated that after experimental pancreatic duct ligation (PDL), most of the acinar cells are rapidly and mas-
sively deleted by apoptosis-mediated exocrine atrophy. This process is also regulated by p53 active  protein13,16–19. 
In this regard, our group has demonstrated a complete acinar cell deletion both in short and long-term evolution 
with no sign of acinar regeneration after an efficient model of PDL in murine and also in pig normal  pancreas20,21.
Taken these pieces of evidences in mind, our hypothesis is that selective PDL in Ptf1a-Cre (+/ki); K-ras LSLG-
12Vgeo (+/ki) mice at an early stage (in the absence of p53 inactivation) can induce apoptotic-mediated exocrine 
atrophy, and may avoid progression to PDAC, overcoming pro-oncogenic stimulation. To study this, we examined 
the histological changes and the gene expression that take place in the distal and proximal pancreas after PDL.
Materials and methods
Study design. Twelve-week old Ptf1a-Cre (+/ki); K-ras LSLG12Vgeo (+/ki) mice referred as Kras mice and two 
control groups K-RasLSLG12Vgeo(+/ki) mice and Ptf1a-Cre(+/ki) mice referred to as G and Cre mice  respectively22,23 
were used in this study. All animals were bred and raised until 8–10  weeks at the Spanish National Cancer 
Research Center (CNIO, Madrid), then imported to Barcelona’s Biomedical Research Park (PRBB) facilities. 
The research protocol was approved by the Ethics Committee for Animal Experimentation of PRBB (Ref.: FBP-
12-1422) and the study was conducted according to the approved guidelines of the Government of Catalonia’s 
Animal Care Committee (Ref.: DAAM 6529). All experiments were performed in accordance with relevant 
guidelines and regulations.
Kras mice were divided in three experimental groups: non operated animals referred to as “control group” 
(n = 13), animals that were operated and surgically manipulated but did not undergo pancreatic ligation referred 
to as “sham group” (n = 8) and animals subjected to a pancreatic duct ligation referred to as “PDL group” (n = 26). 
Mice were sacrificed and analyzed 1, 3 and 6 months postoperatively (PO). Additionally, G (n = 12) and Cre mice 
(n = 11) were also subjected to PDL and were sacrificed at the same PO periods.
Surgical technique. At 12 weeks of age, the peritoneal cavity was accessed through a midline laparotomy, 
under anesthetic induction with isoflurane at 4% and at 2.5% maintenance in 100% oxygen. The stomach, pan-
creas and spleen were mobilized as described  previously19,24 in all the animals subjected to surgery (sham and 
PDL groups). In PDL group mice, dissection and ligation of the splenic lobe of the pancreas were performed on 
the right side of the superior mesenteric vein, using 8/0 polyglycolic acid suture (Fig. 1). Special caution with 
Figure 1.  Surgical ligation of splenic pancreatic lobe in Ptf1a-Cre(+/ki); K-ras  LSLG12Vgeo(+/ki) mice. Pancreatic 
ligation was performed including the main splenic pancreatic duct adjacent to the superior mesenteric vein. 
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this technique was observed with the preservation of the gastroepiploic pedicle so that any ischemic effect on the 
pancreas and the spleen is avoided.
The pancreas and the abdominal viscera were finally relocated to their anatomical position, and the midline 
incision was sutured in two layers (aponeurotic plane with 4/0 absorbable continuous suture, and skin with 4/0 
silk interrupted suture) in mice from the PDL and sham groups.
Postoperative care and necropsy. Animals were monitored for signs of stress and followed up for 1, 3 
or 6 months. At each of these PO periods, some mice of each group were euthanatized with  CO2 inhalation to 
explore the peritoneal cavity. The pancreas, the spleen and a segment of the duodenum were simultaneously 
removed. The ligature, if present (see Fig. 2B,F), was noted and the splenic lobe was transected and referred as 
distal pancreas (DP) for further analysis. The other lobes (gastric and duodenal) were referred to as proximal 
pancreas (PP). The animals were euthanatized by inhalation of 70–90%  CO2.
Histological study. Specimens were formalin-fixed and embedded in paraffin. Each pancreas was serially 
sectioned (3 µm). A total of 11,200 slides were considered and a selection of 568 Sections (8 slides per animal, 
70 mice in total) was stained with hematoxylin and eosin and reviewed blindly by an expert pathologist. Every 
Figure 2.  Histological aspects of PDL in Ptf1a-Cre(+/ki); K-ras  LSLG12Vgeo(+/ki) mice. i. Macroscopic aspect of 
a Kras pancreas in a control or sham mice (A). Both proximal (C) and distal pancreas (D) developed PanIN1 
(G), PanIN 2 (H), PanIN 3 (I) and AFL. (J). ii. Macroscopic aspect of a Kras pancreas of PDL mice (B). Note the 
atrophic aspect of the ligated distal pancreas which is shrunk to a small portion of the tissue close to the spleen 
(on the right of the ligature). Proximal pancreas (E) developed PanIN 1 (G), PanIN 2 (H), PanIN 3 (I) and 
AFL (J), while distal pancreas (F) was characterized by an atrophic pattern. Note preserved parenchyma before 
the ligature (arrow) and atrophic distal pancreas. Few PanIN 1 lesions and AFL were identified in the distal 
pancreas (K). But also an atrophic duct with an apoptotic cell (arrow), showing a pycnotic and irregular nucleus 
and surrounding the ducts moderate chronic inflammation (L). d duodenum, s spleen, lig ligature, PP proximal 
pancreas, PD distal pancreas. Scale bars (C–D and G–L): 50 μm. Scale bars (E–F): 200 μm.
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preneoplasic lesion (PanIN 1 to PanIN 3 and AFLs), defined according to the 2006  Consensus25, was noted and 
 counted6,26.
Gene expression assays. Kras-PDL mice of different PO periods with enough quantity of atrophic distal 
pancreas to perform manual macroscopic dissection were selected for microarray analysis. The formalin-fixed, 
paraffin-embedded PP and DP of Kras-PDL mice were processed as previously  described27. Briefly, total RNA 
was then isolated using the RecoverAll Total Nucleic Acid Isolation Kit (Life Technologies) from 40 serial sec-
tions with a thickness of 3 µm for each of the portions of the pancreas (PP and DP).
RNA quantity and purity was determined on the ND-2000 Spectrophotometer (NanoDrop Technologies) and 
RNA integrity was assessed using Agilent 2100 Bioanalyzer (Agilent Technologies). As RNA integrity number 
(RIN) obtained from Bioanalyzer is not informative for FFPE samples, the percentage of RNA > 200nt was used 
as an estimation of RNA integrity for each sample.
For microarrays analysis, amplification, labeling and hybridizations were performed according to protocol 
GeneChip Pico Reagent kit (Affymetrix). The working conditions used were 50 ng input RNA, 12 cycles of 
pre-PCR and 16 h of IVT. After the sample processing it was hybridized to GeneChip Mouse Clariom S Array 
(Affymetrix) in a GeneChip Hybridization Oven 640. Washing and scanning were performed using the Expres-
sion Wash and Stain and the GeneChip System of Affymetrix (GeneChip Fluidics Station 450 and GeneChip 
Scanner 3000 7G).
Microarray data processing and gene expression analysis. Quality control was performed on the 
raw data CEL files corresponding to 5 paired Kras-PDL mice (DP and PP) samples with arrayQualityMetrics 
 package28. Once quality checked, preprocessing of the data was executed with oligo  package29. Normalization 
was performed using Robust Multi-array Average (RMA) algorithm which creates an expression matrix from 
Affymetrix data. The raw intensity values were background corrected, log2 transformed and then quantile nor-
malized. Probes were annotated using annotateEset function and pd.clariom.s.mouse annotation data from the 
affycoretools  package30. Next, a linear model was fit to the normalized data to obtain an expression measure for 
each probe set on each array. Before performing the differential gene expression analysis, the expression matrix 
obtained after RMA normalization was filtered by the Inter-quantile range (IQR) which provides a measure 
of the spread of the middle 50% of the intensity scores for each gene. Differential expression analysis was per-
formed for paired samples using  Limma31 (Linear Models for Microarray Data) package. Normalized expression 
matrix was used as input for Gene Set Enrichment Analysis (GSEA). Genesets with an FDR < 0.25 were consid-
ered significant.
Human samples. Human pancreatic samples were obtained from patients who had undergone pancrea-
toduodenectomy (PD) with ductal occlusion of the remnant pancreas at the Parc de Salut Mar and had a primary 
diagnosis of PDAC or distal cholangiocarcinoma during the period 2012–2014. The protocol was approved by 
the Ethical Committee (CEIC-2012-130) of our institution (Hospital del Mar, Barcelona, Spain) and informed 
consent was obtained from all patients. All methods were performed in accordance with relevant guidelines and 
regulations for human subjects. In these selected cases, ductal occlusion of the main pancreatic duct of the distal 
remnant of the pancreas (without pancreatic anastomosis) was performed similarly the procedure described by 
Fromm et al.32 These patients provided a unique opportunity to study morphologic changes of the pancreas after 
pancreatic duct occlusion according to the evaluation of appearance on  CT33,34 during the PO period. In addi-
tion, mutation analysis of exon 2, 3 and 4 of the KRAS gene was performed after manual or laser microdissection 
of precursor lesions in resected pancreas specimens.
Statistical analysis. Data are presented as mean and standard deviation (SD). Non-parametric tests (Chi-
Square, U-Mann Whitney and Kruskal–Wallis) were employed for univariate analysis. For exposing purposes, 
premalignant lesions were evaluated independently in PanIN 1 and higher grade premalignant lesions (HGPL) 
including PanIN 2, PanIN 3 and AFL. Linear regression models were performed in order to determine the 
best-fit equation for the number of lesions during follow-up for PanIN1 and HGPL. In addition, factors found 
to be significant predictors in the univariate analysis were subjected to multivariate analysis (backward stepwise 
logistic regression analysis). Results were expressed as Odds Ratio (OR) with a 95% confidence interval (CI). 
Differences were considered to be significant at a threshold of p < 0.05. Statistical analyses were performed with 
statistical software (SPSS version 19.0; SPSS, Inc, Chicago, Ill).
Results
Model validation. All animals tolerated the surgical procedure well and recovered and ambulated promptly. 
In the immediate PO period (4 days) the animals showed signs of stress and discomfort such as bristling hair or 
lack of grooming, as expected in a normal PO context. Later on, there were no signs of relevant disease in the PO 
follow-up and the Kras mice showed a normal growth curve, displaying no differences between groups.
As expected, premalignant lesions were not observed in control mice in which the conditional mutant Kras 
allele was not activated in the pancreas (Cre and G mice). In the Kras mice, we identified a majority of PanIN 
1 lesions (n = 6290; 97%), followed in number by AFL (n = 160; 2.5%), PanIN 2 and PanIN 3 high-grade lesions 
(n = 32; 0.4% and n = 10; 0.1%, respectively) and frequent areas of focal lobulicentric atrophy (patchy atrophy) as 
already described in these  models26. Therefore, hereinafter the results refer only to Kras mice. The time-course 
development of lesions is shown in Fig. 2.
Histologically, consistent with other PDL  models14,21,35, the DP showed an intense pattern of atrophy with 
an increase of adipose and fibrosis over the PO periods. There also seemed to be an extension of adipose tissue 
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surrounding the pancreatic tissue. More specifically, there was a complete replacement of exocrine acini by pseu-
doductal complexes, based on apparently novel duct-like structures composed of low cuboidal cells (Fig. 2F,K) 
(severe atrophy). There were also scattered infiltrates of lymphocytes and plasma cells in the fibrous boundary.
The number of PanIN 1 lesions in the ligated pancreas is reduced. All mice presented an increase 
of PanIN 1 lesions in the PP over time, without differences among groups (best-fit less squared function was 
obtained with a linear model; r = 0.57, p < 0.01). A similar increase was observed in the DP in the sham and con-
trol groups over the PO, but not in the PDL group. In fact, the number of PanIN 1 lesions in the PDL group was 
significantly lower in DP compared to its corresponding value in PP at each PO time being almost 24-fold lower 
at 6 months PO. Furthermore, the number of PanIN 1 lesion in DP was significantly lower (p < 0.01) in the PDL 
group at 6 months PO compared to the sham and control group (Fig. 3A).
Figure 3.  Evolution of preneoplasic lesions after PDL. Mean number of PanIN 1 (A) and HGPL (B) per mouse 
in each group over PO time. *Statistically significant (p < 0.05) comparing values between PDL vs. sham/control 
at DP after 6 month PO; †Statistically significant (p < 0.05) comparing PP vs. DP for each group and PO period, 
‡: p = 0.05.
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The number of HGPL in the ligated pancreas is reduced. Similarly to PanIN1 lesions, the number 
of HGPL in the PP usually increased over time in all groups and there were no significant differences between 
groups in any PO time. This increase was also observed in the DP of mice in the sham and control groups, which 
increased significantly over time following a linear model (r = 0.56, p < 0.01). Again, the number of HGPL in the 
PDL group was significantly lower in DP compared to its corresponding value in the PP at 3 and 6 months PO, 
being almost 22-fold lower at 6 months PO. Similarly to PanIN1 lesions, the number of HGPL in DP was sig-
nificantly lower (p < 0.01) in the PDL group at 6 months PO compared to the sham and control group (Fig. 3B).
The risk of developing HGPL is reduced in the ligated pancreas. In the univariant and multivariant 
analyses two variables demonstrated a significant influence on the presence of HGPL: postoperative time and 
experimental group. Thus, the increase of PO time was associated with 3 times more risk of HGPL (OR: 2.9, IC 
95% 1.09–8.02, p = 0.03).
Having undergone PDL was protective for the development of HGPL: the risk of having HGPL was 6.87-
fold higher in the control group (IC 95% 1.21–39.17, p = 0.03) and 9.84-fold higher in the sham group (IC 95% 
1.21–785.92, p = 0.028) than in the PDL group.
A statistically significant decrease in the number of HGPL and PanIN 1 was observed when severe atrophy was 
seen in the studied segment of the pancreas (Fig. 4). On the contrary, patchy atrophy was linked to a significant 
increase in the number of HGPL and PanIN 1 (Fig. 4).
Transcriptional analysis reveals downregulation of the acinar program in distal pancreas. Dif-
ferential expression analysis using Limma revealed 38 significant differentially expressed genes after p-value 
adjustment for multiple testing; 36 of those were downregulated and 2 upregulated in the distal portion of the 
ligated pancreas. The vast majority of downregulated genes corresponded to acinar enzymes or were related to 
the acinar function. (Table 1, Fig. 5A). Gene Set Enrichment analysis supported this downregulation of the aci-
nar function in the distal pancreas of Kras-PDL mice. (Fig. 5B).
Human experience in the ligated pancreas. Finally, to assess whether these effects were relevant to 
patients, we examined the pancreas of four patients with primary tumors in whom the distal pancreas was 
ligated after pancreatoduodenectomy (PD) that also contained PanIN1 and HGPL (see a representative case in 
Fig. 6). In all cases, the distal remnant pancreas (body and tail) was characterized by an atrophic pattern based 
on the CT analysis as it has been described in previous studies after  PD33,34. The mean rate reduction of the pan-
creatic parenchymal thickness measured at the cross-section of its body after 12 and 24 months was 25 ± 15% 
and 47 ± 11%, respectively. An important ductal dilatation of the main pancreatic duct was also observed. In two 
of the cases exon 2 mutated to p.G12D and p.G12V. These observations are highly reminiscent of the findings 
in mice.
Discussion
Many conventional therapies for pancreatic cancer aim to induce cellular damage to trigger apoptosis. In fact, 
apoptosis is an evolutionary designed method of preventing propagations of mutations or simply to eliminate 
unwanted or useless  cells36. Mutated or useless cells are better dead and cell suicide through apoptosis may 
achieve this goal and this could be relevant in many diseases. For example, in acute pancreatitis, the extent of 
pancreatic acinar cell apoptosis has been shown to be inversely related to the severity of the disease and induc-
tion of apoptosis in animal models has been found to have a protective effect against acute  pancreatitis37. In 
Figure 4.  Types of atrophy in pancreas of Ptf1a-Cre(+/ki); K-ras  LSLG12Vgeo(+/ki mice. When severe pancreatic 
atrophy (A.B) was present in the specimen (in DP of PDL-Kras mice) then PanIN 1 (C) and HGPL (D) were 
less frequently present than when there was no severe atrophy. On the contrary, when patchy atrophy (E,F) was 
observed in the specimen (in PP of control, sham and PDL-group and in DP of control and sham group) then 
PanIN 1 (G) and HGPL (H) were more frequently present than when patchy atrophy was absent. Bar errors 
including mean value and 95% confidence interval. *p < 0.05; **p < 0.01; #p = 0.059. Scale bars: 50 μm.
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other diseases like PDAC of the proximal pancreas, complete occlusion of the main pancreatic duct with the 
corresponding massive atrophy of the distal pancreas is  frequent38 (see Fig. 7). In that regard, it has usually been 
recognized that complete occlusion of the main duct of exocrine glands leads to the deletion of acinar cells by a 
massive and rapid apoptosis phenomenon. This has been demonstrated in the  pancreas16–19 and also in salivary 
 glands39. We previously studied these phenomena with an efficient model of PDL in normal murine and normal 
pig pancreas in vivo20,21 and we confirmed a massive deletion of exocrine cells through apoptosis while preserv-
ing the endocrine tissue. In the present study we triggered the same physiological mechanism but in Kras mice 
at an early stage (when p53 is still active) in order to wipe out these potentially pro-oncogenic cells with a long 
period of follow-up (up to 6 months) in comparison to several intergroup controls (control and sham group) 
and intragroup controls (proximal pancreas). Very recently, two  reports40,41 have described the influence of duct 
obstruction on the remaining distal pancreas in Kras mouse models at the cellular level but without quantitative 
analysis of preneoplastic lesions. Both of them described similar signs of strong atrophy and a complete loss of 
the acinar compartment with a ductal replacement but while Shi et al.40 described less preneoplastic lesions in 
the acinar differentiation models in the distal pancreas, Cheng et al.41 observed a higher number of proliferative 
non-mucinous cells of both acinar and ductal origins at 2 weeks after PDL, without severe nuclear atypia or 
tumoral infiltration after 5-month of follow up.
Table 1.  Gene name, fold change and p-value of differentially expressed genes between PP and DP following 
PDL in Ptf1a-Cre(+/ki); K-ras  LSLG12Vgeo(+/ki mice. 38 genes were selected with a p-value < 0.05.
Gene symbol Gene name logFoldChange adj.P.Val
Cel Carboxyl ester lipase − 3.63 0.0002
Sycn Syncollin − 3.42 0.0012
Klk1 Kallikrein 1 − 3.01 0.0014
Pnliprp1 Pancreatic lipase related protein 1 − 3.04 0.0014
Nupr1 Nuclear protein transcription regulator 1 − 2.82 0.0016
Gm5409 Predicted pseudogene 5409 − 2.42 0.0017
Try5 Trypsin 5 − 2.92 0.0017
2210010C04Rik RIKEN cDNA 2210010C04 gene − 2.14 0.0019
Prss1 Protease, serine 1 (trypsin 1) − 2.74 0.0020
Prss2 Protease, serine 2 − 2.93 0.0020
Rnase1 Ribonuclease, RNase A family, 1 (pancreatic) − 4.17 0.0024
Zg16 Zymogen granule protein 16 − 2.23 0.0024
Cpb1 Carboxypeptidase B1 (tissue) − 2.71 0.0025
Try10 Trypsin 10 − 2.42 0.0025
Gm5771 Predicted gene 5771 − 2.30 0.0026
Cpa1 Carboxypeptidase A1, pancreatic − 2.51 0.0026
Ctrl Chymotrypsin-like − 2.55 0.0030
Cela2a Chymotrypsin-like elastase family, member 2A − 2.39 0.0030
Cela1 Chymotrypsin-like elastase family, member 1 − 2.07 0.0049
Gp2 Glycoprotein 2 (zymogen granule membrane) − 2.29 0.0068
Clps Colipase, pancreatic − 3.26 0.0070
Pnlip Pancreatic lipase − 1.70 0.0070
Try4 Trypsin 4 − 2.58 0.0070
Cpa2 Carboxypeptidase A2, pancreatic − 2.91 0.0073
Pnliprp2 Pancreatic lipase-related protein 2 − 2.24 0.0077
Ctrb1 Chymotrypsinogen B1 − 3.45 0.0089
Amy2a1 Amylase 2a1 − 3.10 0.0095
Cela3b Chymotrypsin-like elastase family, member 3B − 2.23 0.0095
Cela3a Chymotrypsin-like elastase family, member 3A − 1.89 0.0152
Mt1 Metallothionein 1 − 2.05 0.0162
Nhsl1 NHS-like 1 1.55 0.0181
Dmbt1 Deleted in malignant brain tumors 1 − 1.55 0.0189
Ggt1 Gamma-glutamyltransferase 1 − 2.10 0.0260
Reg1 Regenerating islet-derived 1 − 2.39 0.0283
Gm10334 Predicted gene 10334 − 1.50 0.0304
Tff2 Trefoil factor 2 (spasmolytic protein 1) − 2.96 0.0429
Srpr Signal recognition particle receptor (docking protein) − 1.31 0.0488
Zdhhc16 Zinc finger, DHHC domain containing 16 2.04 0.0491
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In our study, after a long follow-up (up to 6 months) and an exhaustive quantitative analysis, both the global 
evaluation of premalignant lesions (PanIN 1 and HGPL) and the risk of the apparition of them in a single animal 
were found to be dramatically lower in DP than in PP (more than 20 times lower) in PDL group and significantly 
lower than in sham and control groups.
Interestingly, animals with PDL experienced a marked reduction of the DP (severe atrophy) with preserva-
tion of the proximal one and this phenomenon was linked to a lower number of PanIN 1 and HPGL. In fact, the 
signs of severe atrophy of the distal pancreas after ligation were already evident through gross examination of 
the specimens at 1, 3 and 6 months PO (see the small remaining tissue of DP in Fig. 2B) and matched well with 
the corresponding microscopic examination of a complete acinar dropout. A similar atrophic pattern was seen 
spontaneously after occlusion of the main pancreatic duct by a proximal tumor in  patients38 (Fig. 7) or over time 
in a very selective group of patients in which the remaining distal pancreas was ligated after pancreaticoduo-
denectomy based on the CT analysis (Fig. 6).
In the gene expression analysis of the animals, an expected reduction in pancreatic secretion was evident in 
DP samples of the PDL group. Interestingly, some top genes previously related to the development of preneoplas-
tic lesions or PDAC had been upregulated in PP compared to DP like Sycn42, Dmbt143, Klk144 and mainly Nupr1. 
This last gene cooperates with KrasG12D to induce PanIN formation and pancreatic ductal adenocarcinoma 
development in  mice45–47 (Fig. 5).
Our results are consistent with previous literature in which patchy atrophy accompanied by areas of acino-
ductal metaplasia was constantly described in Kras models and usually linked to premalignant  lesions6,25,48,49. 
Patchy atrophy has also been related to the presence of PanIN lesions in patients with familial predisposition to 
 PDAC6,14. Acinar to ductal metaplasia has been associated with PanIN lesions and many acini in the lobules of 
lobulicentric atrophy described earlier are often characterized by prominent acinar-ductal  metaplasia14,26. How-
ever, it has been serendipitously stated that when the atrophy is severe (> 90% loss of acini and ducts) is unusual 
to see PanIN lesions at least in the resected human pancreas without  adenocarcinoma50. These findings are also 
in agreement with the currently accepted origin of PanIN lesions: observations indicate that the ductal-like cells 
present in PanINs rarely arise by the transformation of normal duct cells. Instead, PanINs may originate either 
Figure 5.  Differential gene expression after PDL. Hierarchical cluster heat-map of 38 differentially expressed 
genes between pancreatic segments (p-value < 0.05) (A). Volcano plot showing significative expressed genes, 
some of which are previously related to PDAC tumorigenesis (blue: upregulated in PP; yellow: upregulated in 
DP) (p-value < 0.05) (B). Gene Set Enrichment Analysis supports downregulation of the acinar function in the 
distal pancreas of Kras-PDL mice after ligation (p < 0.05) (C).
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by transdifferentiation of acinar cells or by misdifferentiation of their  precursors23,51,52. Therefore, the transfor-
mation to PanIN lesions of these acinar cells or their precursors could be interrupted when an early obstruction 
of the main pancreatic duct is performed even when Kras pro-oncogenic stimulation is present. This could be a 
potential research line of interest in some cancerous risk patients taken into account that: (1) Complete occlusion 
of the main pancreatic duct could trigger a physiological protective effect to avoid malignancies in pancreas har-
boring Kras mutations without the aid of any other potentially dangerous treatments as it has been seen before; 
(2) This procedure could be feasible both surgically and  endoscopically53; (3) Kras mutations are believed to be a 
common initiator of mucinous lesions and other cancer precursor  lesions54 and (4) More than 90% of pancreatic 
adenocarcinomas harbor activating mutations in Kras for which targeted therapies have been notoriously inef-
fective across all cancer types prompting the perception that RAS is  undruggable54. However, some limitations 
of this research must also be addressed: All the experiences were done in mice models in which early pancreatic 
lesions are evaluated after duct obstruction. Therefore, the final effect of duct obstruction on established PDAC 
especially in humans are beyond the scope of this study and could be detrimental for its evolution.
In conclusion, Pancreatic duct ligation in Ptf1a-Cre(+/ki); K-ras  LSLG12Vgeo(+/ki) mice induces a decrease in 
the presence of premalignant lesions in the ligated distal pancreas. This could be a potential line of research of 
interest in some cancerous risk patients.
Figure 6.  Human ligated pancreas. CT before pancreatoduodenectomy: head (A), body (B) and tail (D) of the 
pancreas (red arrows). CT after 2 years of the pancreatoduodenectomy (C,E). Note the reduction of the body 
(C) and tail (E) of the remaining pancreas. Hematoxylin–eosin stains of the resected head of the pancreas in 
which we can recognize the tumor (a), PanIN 1(b), PanIN 2 (c) and PanIN 3 (d).
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